EVE Shares EVE Health Group Limited
ACCUMULATE ASX · ASXEnergy-adjacent resource optionality provides speculative upside from asset development progress.
Signal breakdown
- ▸Very small-cap catalyst profile with limited liquidity.
- ▾Below 50-day MA (-16.24%)
- ▸Volume 2.39× average — accumulation
Is EVE a buy right now?
Trend: EVE is trading below the 50-day average (-35.00%), RSI 56 — neutral momentum, with a 3-month return of -23.53%.
Valuation & quality: EVE Health Group Limited trades on price-to-book 1.18; fundamentals show net margin -164.0%, return on equity -50.4%, revenue growth -28.6% year on year.
Our screen: ACCUMULATE (score 1) — Energy-adjacent resource optionality provides speculative upside from asset development progress.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +50.00% | -33.30% | +0.00% | +0.00% | -50.00% | +0.00% | +0.00% |
Fundamentals
Technical signals
About EVE Health Group Limited
EVE Health Group Limited, a life sciences and healthcare company, engages in the development and commercialization of pharmaceutical products in Australia. It operates in two segments, Meluka (Branded Wellness Consumer Products) and Nextract (Pharmaceutical Products and Intellectual Property).
Sector: Consumer Defensive · Industry: Packaged Foods · Australia · Website
Related Energy picks
Browse: all ASX stocks · Energy picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.